吸入麻醉市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球吸入麻醉市場價值為 18 億美元，預計到 2034 年將以 6.2% 的複合年成長率成長至 32 億美元。

這一趨勢受到慢性病發病率上升和老齡化人口成長的推動，這兩者都導致外科手術需求不斷成長。吸入麻醉是一種快速、非侵入性且有效的麻醉方法，因此在醫療機構中廣泛使用。其快速起效和快速恢復的特性增強了其在常規和複雜手術中的吸引力。外科基礎設施投資的不斷增加以及門診手術數量的成長，促使醫療機構採用精準、安全、高效的麻醉劑。

麻醉輸送技術的不斷進步正在改變臨床療效。整合蒸發器、呼出二氧化碳監測和自動藥物分配的增強型系統有助於最大限度地減少人為錯誤並提高給藥準確性。配備人工智慧監控和閉迴路輸送的智慧系統進一步最佳化了揮發性麻醉藥的使用，同時縮短了患者的恢復時間。這些創新正在減少藥物浪費並提高安全性，有助於擴大醫院和門診的市場規模。快速起效和更短恢復期的藥物符合門診和當日手術中心日益成長的營運需求，從而刺激了市場需求。

2024年，七氟醚的銷售額達到13億美元，持續維持在吸入麻醉市場的領先地位。其快速起效和恢復等臨床優勢使其成為首選藥物，尤其是在門診和兒科護理領域。七氟醚面罩誘導平穩、氣道刺激小，且與低流量技術相容，使其在醫療保健系統中廣泛應用，旨在降低麻醉暴露量的同時保持療效。

2024年，維持麻醉領域佔了67.7%的市場佔有率，這得益於其在複雜且長時間的外科手術中維持麻醉的重要作用。心臟病學、神經病學、腫瘤學和骨科等醫學專科的手術數量不斷增加，持續推動該領域的發展。異氟烷、地氟烷和七氟烷等揮發性麻醉劑因其在長時間手術中的可靠性和適應性，仍然是首選。此外，門診患者快速康復的需求也增強了對高效維持麻醉劑的需求。

2024年，北美吸入麻醉市場佔51.7%的市佔率。其領先地位源自於發達的醫療生態系統、高手術量以及先進麻醉技術的快速整合。該地區繼續受益於訓練有素的醫療專業人員以及速效麻醉劑在門診的日益普及。美國在推動創新方面發揮著重要作用，這得益於製藥公司和醫療器材製造商之間致力於最佳化吸入麻醉劑輸送的合作。

活躍於全球吸入麻醉市場的主要參與者包括 Baxter、Halocarbon、Linde、Raman & Weil、Fresenius Kabi、Piramal Critical Care、Lunan Pharmaceutical、Troikaa Pharmaceuticals、AbbVie 和 Aetos Pharma。吸入麻醉市場的領先公司正在採取一系列策略性措施來鞏固其全球地位。許多公司正在擴大生產能力並提高供應鏈彈性，以滿足日益成長的外科需求。創新是關鍵重點，特別是透過自動化和整合 AI 驅動的監控來提高輸送系統的安全性和精確度。策略聯盟和許可協議有助於加快市場准入並拓寬治療組合。該公司還透過推出符合當地監管標準的具有成本效益的配方來瞄準新興市場。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 手術量不斷增加
    • 麻醉輸送系統的技術進步
    • 慢性病盛行率不斷上升
    • 全球門診手術中心（ASC）數量增加
  • 產業陷阱與挑戰
    • 設定成本高
    • 術後副作用
  • 市場機會
    • 麻醉回收系統
    • 新興市場的擴張
• 成長潛力分析
• 監管格局
• 投資和融資格局
• 技術格局
  • 新興技術
  • 現有技術
• 定價分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

• 主要趨勢
• 七氟醚
• 地氟烷
• 異氟烷
• 其他產品

第6章：市場估計與預測：按應用，2021 - 2034

• 主要趨勢
• 就職
• 維護

第7章：市場估計與預測：依最終用途，2021 - 2034

• 主要趨勢
• 醫院
• 門診手術中心
• 其他最終用途

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Aetos Pharma
• Baxter
• Fresenius Kabi
• Halocarbon
• Linde
• Lunan Pharmaceutical
• Piramal Critical Care
• Raman & Weil
• Troikaa Pharmaceuticals

The Global Inhalation Anesthesia Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 3.2 billion by 2034.

The trend is supported by the rise in chronic diseases and the growing elderly population, both of which contribute to the increasing demand for surgical procedures. Inhalation anesthesia offers a fast, non-invasive, and effective method of anesthesia delivery, making it widely adopted across healthcare settings. Its ability to allow rapid onset and recovery enhances its appeal in both routine and complex surgeries. Increasing investments in surgical infrastructure and a rise in outpatient procedures are pushing healthcare providers to adopt anesthetic agents that offer precision, safety, and efficiency.

Ongoing advancements in anesthesia delivery technologies are transforming clinical outcomes. Enhanced systems featuring integrated vaporizers, exhaled CO2 monitoring, and automated agent dispensing help minimize human error and improve dosing accuracy. Intelligent systems with AI-enabled monitoring and closed-loop delivery further optimize the use of volatile anesthetics while improving patient recovery timelines. These innovations are reducing drug waste and improving safety, contributing to market expansion across hospital and ambulatory care settings. Agents offering rapid onset and shorter recovery periods align with the growing operational needs of outpatient and same-day surgical centers, boosting demand.

In 2024, the sevoflurane generated USD 1.3 billion, maintaining its leadership in the inhalation anesthesia market. Its clinical advantages, such as a fast onset and recovery profile, continue to make it the preferred agent, especially in outpatient and pediatric care. Sevoflurane's smooth mask induction, minimal airway irritation, and compatibility with low-flow techniques contribute to its widespread use across healthcare systems aiming to reduce anesthetic exposure while maintaining efficacy.

The maintenance segment held a 67.7% share in 2024 due to its essential role in preserving anesthesia during complex and prolonged surgical interventions. The increasing number of surgeries in medical specialties such as cardiology, neurology, oncology, and orthopedic care continues to drive the segment. Volatile agents like isoflurane, desflurane, and sevoflurane remain the top choices due to their reliability and adaptability during extended procedures. Additionally, the need for quick patient recovery in ambulatory care reinforces the demand for efficient maintenance-phase agents.

North America Inhalation Anesthesia Market held a 51.7% share in 2024. Its leadership stems from a well-developed healthcare ecosystem, high procedural volumes, and the rapid integration of advanced anesthesia technology. The region continues to benefit from the presence of highly trained medical professionals and the increasing adoption of fast-acting anesthetics for outpatient use. The U.S. plays a major role in driving innovation, supported by collaborations among pharmaceutical firms and medical device manufacturers focused on optimizing inhalation anesthetic delivery.

Major players active in the Global Inhalation Anesthesia Market include Baxter, Halocarbon, Linde, Raman & Weil, Fresenius Kabi, Piramal Critical Care, Lunan Pharmaceutical, Troikaa Pharmaceuticals, AbbVie, and Aetos Pharma. Leading companies in the Inhalation Anesthesia Market are adopting a mix of strategic initiatives to bolster their global position. Many are expanding production capabilities and improving supply chain resilience to meet increasing surgical demand. A key focus is on innovation, particularly in enhancing the safety and precision of delivery systems through automation and integration of AI-powered monitoring. Strategic alliances and licensing agreements help accelerate market access and widen therapeutic portfolios. Firms are also targeting emerging markets by introducing cost-effective formulations that meet local regulatory standards.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising surgical volume
    • 3.2.1.2 Technological advancement in anesthesia delivery systems
    • 3.2.1.3 Growing prevalence of chronic diseases
    • 3.2.1.4 Global rise in ambulatory surgical centers (ASCs)
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High setup costs
    • 3.2.2.2 Postoperative side effects
  • 3.2.3 Market opportunities
    • 3.2.3.1 Anesthesia recycling systems
    • 3.2.3.2 Expansion in emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Investment and funding landscape
• 3.6 Technological landscape
  • 3.6.1 Emerging technologies
  • 3.6.2 Current technologies
• 3.7 Pricing analysis
• 3.8 Future market trends
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Sevoflurane
• 5.3 Desflurane
• 5.4 Isoflurane
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Induction
• 6.3 Maintenance

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Aetos Pharma
• 9.3 Baxter
• 9.4 Fresenius Kabi
• 9.5 Halocarbon
• 9.6 Linde
• 9.7 Lunan Pharmaceutical
• 9.8 Piramal Critical Care
• 9.9 Raman & Weil
• 9.10 Troikaa Pharmaceuticals